TOWA Pharmaceutical Co (TSE:4553) Net Income From Continuing Operations : 円16,173 Mil (TTM As of Dec. 2023)

View and export this data going back to 2004. Start your Free Trial

What is TOWA Pharmaceutical Co Net Income From Continuing Operations?

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. TOWA Pharmaceutical Co's net income from continuing operations for the three months ended in Dec. 2023 was 円4,566 Mil. Its net income from continuing operations for the trailing twelve months (TTM) ended in Dec. 2023 was 円16,173 Mil.

TOWA Pharmaceutical Co Net Income From Continuing Operations Historical Data

The historical data trend for TOWA Pharmaceutical Co's Net Income From Continuing Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

TOWA Pharmaceutical Co Net Income From Continuing Operations Chart

TOWA Pharmaceutical Co Annual Data

Trend

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

Net Income From Continuing Operations

Get a 7-Day Free Trial

20,709.00

18,728.00

22,246.00

4,605.00

24,459.00

TOWA Pharmaceutical Co Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Net Income From Continuing Operations	Get a 7-Day Free Trial															217.00	4,750.00	2,203.00	4,566.00	4,654.00

TOWA Pharmaceutical Co Net Income From Continuing Operations Calculation

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. It excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Net Income From Continuing Operations for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was 円16,173 Mil.

TOWA Pharmaceutical Co (TSE:4553) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » TOWA Pharmaceutical Co Ltd (TSE:4553) » Definitions » Net Income From Continuing Operations

Comparable Companies

Traded in Other Exchanges

6QC:Germany

Address

2-11, Shinbashi-cho, Kadoma, Osaka, JPN, 571-8580

Website

http://www.towayakuhin.co.jp

TOWA Pharmaceutical Co Ltd is a Japan based pharmaceutical company engaged in research and development, production, and marketing of generic drugs. It also provides drug consulting services for patients and their families and relatives. It organizes academic seminars for medical professionals and posts articles in journals. It participates in training for pharmacists. The company has three main plants in operation namely Osaka plant, Okayama plant, and Yamagata plant. Towa has offers more than 500 drugs to meet the diverse therapeutic requirements including lifestyle related diseases such as hypertension and diabetes, digestive system diseases, nervous system diseases and allergic diseases, vitamins and antibiotics.

TOWA Pharmaceutical Co (TSE:4553) Headlines

No Headlines